Shares of Health Care sector company Summit Therapeutics moved -2.5% today, and are now trading at a price of $18.46. The Large-Cap stock's daily volume was 907,687 compared to its average volume of 5,185,747. The S&P 500 index returned a 1.0% performance.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company is based in Miami and has 105 full time employees. Its market capitalization is $13,967,259,648.
4 analysts are following Summit Therapeutics and have set target prices ranging from $17.869 to $34.799 per share. On average, they have given the company a rating of buy. At today's prices, SMMT is trading -31.71% away from its average analyst target price of $27.03 per share.
Over the last year, SMMT's share price has increased by 720.4%, which represents a difference of 688.4% when compared to the S&P 500. The stock's 52 week high is $33.89 per share whereas its 52 week low is $2.05. Summit Therapeutics has averaged free cash flows of $-49658500.0 over the last 5 years, with a mean growth rate of -28.2%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | -76,760 | 128 | -76,888 | -82.17 |
| 2022 | -41,582 | 624 | -42,206 | 42.1 |
| 2021 | -72,587 | 306 | -72,893 | -50.2 |
| 2020 | -48,111 | 421 | -48,532 | -37.63 |
| 2019 | -35,106 | 157 | -35,263 | -59.06 |
| 2018 | -21,501 | 668 | -22,169 |
